

[Home](#) > Nontaxane OK'd for metastatic breast cancer

Generic Name:

Eribulin

Trade Name:

Halaven

Company:

Eisai

Notes:

[Eribulin](#) is a nontaxane microtubule dynamics inhibitor indicated for patients who have previously received at least two chemotherapeutic regimens for treatment of their metastatic breast cancer. The recommended dose is 1.4 mg/m² given I.V. over 2 to 5 minutes on days 1 and 8 of a 21-day cycle. [FDA](#) approved the drug based on data from an open-label trial showed that treatment with eribulin improved overall survival compared with a control treatment regimen, resulting in a median response duration of 4.2 months. Common adverse events observed with therapy were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.

Medication Monitor Categories:

[New Drug Approvals](#)

Use:

Treatment of metastatic breast cancer

Source URL: <https://www.aphadruginfoline.com/new-drug-approvals/nontaxane-okd-metastatic-breast-cancer>